References
- Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476–2486.
- Vaduganathan M, Patel RB, Michel A, et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;69:556–569.
- Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: report from a national heart, lung, and blood institute and heart rhythm society workshop. Circulation. 2010;122:2335–2348.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–781.
- Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
- Tseng ZH, Olgin JE, Vittinghoff E, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD Study. Circulation. 2018;137:2689–2700.
- Chatterjee NA, Moorthy MV, Pester J, et al. Sudden death in patients with coronary heart disease without severe systolic dysfunction. JAMA Cardiol. 2018;3:591–600.
- Adabag S, Rector TS, Anand IS, et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2014;16:1175–1182.
- Vaduganathan M, Claggett BL, Chatterjee NA, et al. Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail. 2018;6:653–661.
- Silverman MG, Patel B, Blankstein R, et al. Impact of race, ethnicity, and multimodality biomarkers on the incidence of new-onset heart failure with preserved ejection fraction (from the multi-ethnic study of atherosclerosis). Am J Cardiol. 2016;117:1474–1481.
- Goyal P, Paul T, Almarzooq ZI, et al. Sex- and race-related differences in characteristics and outcomes of hospitalizations for heart failure with preserved ejection fraction. J Am Heart Assoc. 2017;6.
- Okin PM, Kjeldsen SE, Julius S, et al. Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. Heart Rhythm. 2012;9:531–537.
- Kato S, Saito N, Kirigaya H, et al. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol. 2015;191:314–319.
- Fallavollita JA, Heavey BM, Luisi AJ Jr., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–149.
- Kutyifa V, Beck C, Brown MW, et al. Multicenter automatic defibrillator implantation trial-subcutaneous implantable cardioverter defibrillator (MADIT S-ICD): design and clinical protocol. Am Heart J. 2017;189:158–166.